HLX 43
Alternative Names: Anti-PD-L1 ADC; HLX-43Latest Information Update: 15 Dec 2023
At a glance
- Originator Shanghai Henlius Biotech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Dec 2023 US FDA approves IND application for HLX 43 in Solid tumours (Shanghai Henlius Biotech, pipeline December 2023)
- 28 Nov 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (Parenteral, Injection) (NCT06115642)
- 27 Oct 2023 Chinese National Medical Products Administration (NMPA) approves IND application for HLX 43 in Solid tumours